The Nascent Psychedelic Industry is Booming as Several Companies Have Gone Public and More are Expected to Follow This Route in 2021 to Attract More Capital From Institutional and Retail Investors
Competition among the dozens of biopharmaceutical companies is fierce. Many are seeking more capital to conduct expensive and lengthy drug trials and develop intellectual property to synthesize the molecules to help treat various mental disorders. The companies that can bring their Psychedelic drugs to the market first will emerge from the pack and could likely hit a home run. “Within the next six to 12 months, we will see an arms race in the psychedelic space as companies try to innovate and get their drugs to trials and to the market,” says Jason Spatafora, co-founder of MarijuanaStocks.com and head trader at TrueTradingGroup.com. ATAI Life Sciences, a Berlin-based biotech company that is researching both Psychedelic and nonpsychedelic compounds, is expected to go public in 2021
New York, NY – December 21, 2020 – Investments continued flowing into the psychedelic medicine sector this year and will likely continue in 2021 as mental illness cases rise across the globe. The World Health Organization (WHO) estimates that
700 million cases of mental and neurological disorders are reported annually, accounting for 13% of global disease burden. Of course, these are only reported cases, so the number is likely much higher and will likely rise further due to the ongoing health crisis. Luckily, growing awareness around mental illness has led to a slew of research and development for effective novel treatments to help combat the growing mental health crisis. Psychedelic medicine for mental illness is one area that has gained the spotlight after
Psychedelics Industry Gearing Up For an Even Bigger 2021
- FN Media Group Presents Microsmallcap.com Market Commentary
NEW YORK, Dec. 21, 2020 /PRNewswire/ Investments continued flowing into the psychedelic medicine sector this year and will likely continue in 2021 as mental illness cases rise across the globe. The World Health Organization (WHO) estimates that
700 million cases of mental and neurological disorders are reported annually, accounting for 13% of global disease burden. Of course, these are only reported cases, so the number is likely much higher and will likely rise further due to the ongoing health crisis. Luckily, growing awareness around mental illness has led to a slew of research and development for effective novel treatments to help combat the growing mental health crisis. Psychedelic medicine for mental illness is one area that has gained the spotlight after
Mydecine Innovations Group Engages ethica CRO as Contract Research Organization Partner for Phase 2A PTSD Clinical Trials - Press Release digitaljournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitaljournal.com Daily Mail and Mail on Sunday newspapers.
Microdose Psychedelic Insights is pleased to present our first custom event series, leveraging the platform strengths of our Psychedelic Operating System.
Mydecine Speakers Series: Psychedelic Innovations is a virtual event that will explore how current research is igniting mainstream medical interest to unlock the potential of psychedelic therapies. We invite you to join us as we explore the incredible findings around current psychedelic research and potential paths to mainstream acceptance. Grab your
free tickets today and join us Dec. 15th from 12:00 – 1:30 pm EST.
Expert Panelists, Fantastic Perspectives
Panelists will be asked to reflect on the past, present, and future potential of the psychedelic space in relation to the mental health crisis. Mydecine Innovation Group‘s very own Robert Roscow (Chief Scientific Officer & Co-Founder), Dr. Rakesh (Chief Medical Officer), and Dr. Robin Carhart-Harris (Scientific Advisory Board Member) will all be speaking.